Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-03. Numbers and descriptions here follow the published literature rather than marketing material.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
== Adverse effects == The New England Journal of Medicine published two editorials in 2003 expressing concern about off-label uses of HGH and the proliferation of advertisements for "HGH-Releasing" dietary supplements, and emphasized that there is no evidence that use of HGH in healthy adults or in geriatric patients is safe and effective – and especially emphasized that risks of long-term HGH treatment are unknown. One editorial was by Jeffrey M. Drazen, M.D., the editor-in-chief of the journal; the other one was by Mary Lee Vance, who provided the NEJM's editorial original, cautious comment on a much cited 1990 study on the use of HGH in geriatric patients with low growth hormone levels. A small but controlled study of GH given to severely ill adults in an intensive care unit setting for the purpose of increasing strength and reducing the muscle wasting of critical illness showed a higher mortality rate for the patients having received GH. The reason is unknown, but GH is now rarely used in ICU patients unless they have severe growth hormone deficiency. GH treatment usually decreases insulin sensitivity, but some studies showed no evidence for increased diabetes incidence in GH-treated adult hypopituitary patients. In past it was believed that GH treatment could increase the cancer risk; a large study recently concluded that "With relatively short follow-up, the overall primary cancer risk in 6840 patients receiving GH as adults was not increased.
== Fictional character biography == Boodikka of the planet Bellatrix was recruited by Chaselon to join the then-reconstituted Green Lantern Corps. Boodikka had previously belonged to the Bellatrix Bombers mercenary group. Initially, Hal Jordan is dismayed and put off by Boodikka's aggressive attitude. Kilowog, a renowned trainer in the Corps and the trainer of Jordan himself, is eager to train someone so challenging and gave her his recommendation as a candidate. Boodikka is opposed to authority and is often at odds with Kreon, a former chieftain who is used to discipline and military precision. Kilowog forces Boodikka and Kreon to battle physical projections of their fears: Kreon's fear of the uncontrollable and Boodikka's fear of the restraints of authority. Boodikka and Kreon agree to swap opponents and defeat them, ultimately reconciling with each other. Boodikka eventually becomes a recruiter for the Corps. She encounters Barin, a young soldier of a kindred warrior species who she believes will prove to be an asset to the group. However, Barin is critically injured in his first battle and placed on life support.
=== Transfer between bacteria === Gram-negative bacteria can develop and transfer β-lactam resistance (including carbapenem resistance) in many ways. They can generate new extended-spectrum β-lactamases (ESBL) from the existing spectrum of plasmid-mediated β-lactamases through amino acid substitution. They can acquire genes encoding ESBL from environmental bacteria. They can increase the expression of chromosome-encoded β-lactamase genes (bla genes) due to regulatory gene and promoter sequence modifications. They can mobilize bla genes through integrons or horizontal transfer of genomic islands into other gram-negative species and strains. They can disseminate plasmid-mediated carbapenemases. Finally, they can lower or even inhibit the expression of porin genes. Three major classes of enzymes are involved in carbapenem resistance: class A carbapenemases, class B metallo-β-lactamases (MBL), and class D β-lactamases (OXA). The four known groups of class A carbapenemases are: SME (three types associated with S. marcescens), IMI (present in E. cloacae), GES (16 variants thus far found in P. aeruginosa predominantly but also found in K. pneumoniae and E. coli), and KPC (10 types of K. pneumoniae carbapenemase). At the UVA Medical Center, a transfer mechanism of KPC-dependent carbapenem resistance was discovered in the transmission of a plasmid carrying the transposon (Tn4401), which contains the KPC gene (blaKPC), to several bacteria including Enterobacter cloacae, Klebsiella oxytoca, E. coli, and Citrobacter freundii.
Public transportation in and around Raleigh is provided by GoRaleigh (formerly Capital Area Transit), which operates 33 fixed bus routes, including the R-Line. Although there are 33 routes, some routes are designed to cover multiple other routes at times when they are not served. Depending on the time of the day, and the day of the week, the number of routes operating is between 5 and 29. Raleigh is also served by GoTriangle (formerly Triangle Transit Authority). GoTriangle offers scheduled, fixed-route regional and commuter bus service between Raleigh and the region's other principal cities of Durham, Cary and Chapel Hill, as well as to and from the Raleigh-Durham International Airport, Research Triangle Park and several of the region's larger suburban communities. Triangle Transit also coordinates an extensive vanpool and rideshare program that serves the region's larger employers and commute destinations. North Carolina State University also maintains its own transit system, the Wolfline, that provides zero-fare bus service to the general public along multiple routes serving the university's campuses in southwest Raleigh. Government agencies throughout the Raleigh-Durham metropolitan area have struggled with determining the best means of providing fixed-rail transit service for the region. From 1995 the cornerstone of Triangle Transit's long-term plan was a 28-mile rail corridor from northeast Raleigh, through downtown Raleigh, Cary, and Research Triangle Park, to Durham using DMU technology.
==== Sleep ==== Sleep disturbances are seen as a possible risk factor for inflammation in Alzheimer's disease. Sleep disruption was previously only seen as a consequence of Alzheimer's disease, but as of 2020, accumulating evidence suggests that this relationship may be bidirectional.
Sources: en.wikipedia.org
== External links == Attorney General Ellison files lawsuit against COVID-19 testing sites, lab for deceiving consumers, Minnesota Attorney General, January 19, 2022 Complaint in State of Minnesota, by its Attorney General, Keith Ellison v. Center for COVID Control, LLC and Doctors Clinical Laboratory, Inc., filed in Hennepin County District Court on January 19, 2022, file # 27-CV-22-731
== American football scandals == Boat Party (2005) – a sex party involving several members of the Minnesota Vikings of the National Football League (NFL) National Football League player conduct controversy (2007–present) – various off the field incidents involving American football athletes from the NFL, including Adam "Pacman" Jones, Terry "Tank" Johnson, Chris Henry, Ben Roethlisberger, Ray Rice, Deshaun Watson, and Adrian Peterson, who earned suspensions as a result. 2007 New England Patriots videotaping controversy (2007) – the New England Patriots were disciplined for videotaping the opposing team's coach's signals. Coach Bill Belichick was fined $500,000 and the New England Patriots were fined $250,000 and lost their 2008 1st-round draft pick. New Orleans Saints bounty scandal (2012) – the NFL discovered that the New Orleans Saints had operated a secret slush fund from 2009 to 2011 that paid "bounties" to defensive players for big plays during games, most controversially for injuring opponents. The scheme was allegedly organized by a number of players plus defensive coordinator Gregg Williams, with the acquiescence of head coach Sean Payton. Shortly after the investigation came to light, Williams was accused of running similar schemes while he was defensive coordinator of the Houston Oilers/Tennessee Titans and Washington Redskins, as well as the head coach of the Buffalo Bills. The league suspended Williams indefinitely and Payton for one year and suspended the Saints' general manager and another assistant for parts of the 2012 season.
fkbB enzyme is responsible of allylmalonyl-CoA synthesis or possibly propionylmalonyl-CoA at C21, which it is an unusual step of general PKS 1. As mentioned, if two methoxymalonyl CoA molecules are substituted for two malonyl-CoA molecules, they will take place in module 7 and 8 (C13 and C15), and fkbA enzyme will enforce this process. After the last step (module 10) of PKS 1, one molecule of L-pipecolic acid formed from L-lysine and catalyzed through fkbL enzyme synthesizes with the molecule from the module 10. The process of L-pipecolic acid synthesis is NRPS enforced by fkbP enzyme. After synthesizing the entire subunits, the molecule is cyclized. After the cyclization, the pre-tacrolimus molecule goes through the post-synthase tailoring steps such as oxidation and S-adenosyl methionine. Particularly fkbM enzyme is responsible of alcohol methylation targeting the alcohol of DHCHC starter unit (Carbon number 31 depicted in brown), and fkbD enzyme is responsible of C9 (depicted in green). After these tailoring steps, the tacrolimus molecule becomes biologically active.
Wingstop opened its first international restaurant in Mexico in 2010. In April 2013, Wingstop announced that they are opening the first store in Southeast Asia, starting in Singapore. In February 2014, Wingstop announced the opening of stores in the Philippines. The first Philippine store opened in June 2014. In the same month, plans were announced for Wingstop to open in Indonesia with 100 stores by 2021. Franchises began opening in London, UK in 2018 and have now grown to 20 locations in the Greater London area. Originally introduced to England by Lemon Pepper Holdings, the majority stakeholder in the franchise is now Sixth Street Partners - the same investment firm that owns the Far West Services franchises on the US West Coast. In 2021, Wingstop made an agreement with JPK Capital to develop 100 Wingstop locations in Canada. The first restaurant in Canada opened in June 2022. In May 2022, Wingstop announced plans to enter South Korea. As of November 26, 2025, Wingstop operates in 15 countries internationally. Recent expansions include Australia, Bahrain, Kuwait, Puerto Rico, Saudi Arabia, and the Netherlands. On this same day, Wingstop reiterated its intentions to expand into Thailand, Italy and Ireland. The first Wingstop in Australia opened on May 17, 2025. The first Dutch outlet opened on August 8 2025, at Amsterdam Airport Schiphol. The first Irish outlet on December 8, 2025 at Dublin's Liffey Valley shopping centre. On December 13, 2025, Wingstop entered the Thailand market, in MBK Center.
At an ultrastructural level the weakening of the corneal tissue is associated with a disruption of the regular arrangement of the collagen layers and collagen fibril orientation. While keratoconus is considered a noninflammatory disorder, one study shows wearing rigid contact lenses by people leads to overexpression of proinflammatory cytokines, such as IL-6, TNF-alpha, ICAM-1, and VCAM-1 in the tear fluid. A genetic predisposition to keratoconus has been observed, with the disease running in certain families, and incidences reported of concordance in identical twins. The frequency of occurrence in close family members is not clearly defined, though it is known to be considerably higher than that in the general population, and studies have obtained estimates ranging between 6% and 19%. Two studies involving isolated, largely homogenetic communities have contrarily mapped putative gene locations to chromosomes 16q and 20q. Most genetic studies agree on an autosomal dominant model of inheritance. A rare, autosomal dominant form of severe keratoconus with anterior polar cataract is caused by a mutation in the seed region of mir-184, a microRNA that is highly expressed in the cornea and anterior lens. Keratoconus is diagnosed more often in people with Down's syndrome, though the reasons for this link have not yet been determined. Researches also have shed light on the role of hormones in the pathophysiology of keratoconus.
Sources: en.wikipedia.org
===== MeSH D08.811.464.267 – carbon-sulfur ligases (EC 6.2) ===== MeSH D08.811.464.267.500 – coenzyme a ligases MeSH D08.811.464.267.500.200 – acetate-coa ligase MeSH D08.811.464.267.500.600 – succinate-coa ligases
== Organization == By NIGMS program mandate, Glue Grant consortia must contain core resources and bridging projects. The EFI consists of six scientific cores which provide bioinformatic, structural, computational, and data management expertise to facilitate functional predictions for enzymes of unknown function targeted by the EFI. At the beginning of the grant, these predictions were tested by five Bridging Projects representing the amidohydrolase, enolase, GST, HAD, and isoprenoid synthase enzyme superfamilies. Three Bridging Projects now remain. In addition, the Anaerobic Enzymology Pilot Project was added in 2014 to explore the Radical SAM superfamily and Glycyl Radical Enzyme superfamily.
=== Other uses === PVDF is used for specialty monofilament fishing lines, sold as fluorocarbon replacements for nylon monofilament. The surface is harder, so it is more resistant to abrasion and sharp fish teeth. Its refractive index is lower than nylon, which makes the line less discernible to fish eyes. It is also denser than nylon, making it sink faster towards fish. PVDF is used for specialty roofing coatings to improve UV resistance and increase roof color retention.
For services to People with Autism and their Families in Oxfordshire. Elizabeth Craig Ovens. Director, McCaskies Butchers. For services to Retail and to the Economy in Scotland. Alfred Oluwafemi Oyekoya. Director, Black Asian Minority Ethnic Mental Health Support. For services to Minority Ethnic Communities in Wales. Caroline Rebecca Paige. For services to Armed Forces Personnel and Veterans. The Reverend Canon Dr. Crispin Alexander Pailing. Member, Merseyside Resilience Forum and Safety Advisory Group. For services to the community in Liverpool, Merseyside. Blair Parham. Director of Music and Principal Conductor, Scottish Fiddle Orchestra. For services to Scottish Music. Satish Manilal Parmar. Senior Policy Adviser, Department for Work and Pensions. For Public Service. Carys Parry. Voluntary Party Manager, Conservative Party. For Political Service. Imran Adam Patel. For services to the community in Blackburn, Lancashire. Wolodymyr Pawluk. Chair, London Branch, Association of Ukrainians in Great Britain and Member, National Executive Committee, Ukrainian Youth Association. For services to the Ukrainian Community. Ewan Benjamin Payne. Team UK Gold Medal Winner, WorldSkills UK. For services to Further Education. Catherine Penny. For services to Plant Heritage and to the community in North Preston, Lancashire. Professor Yvonne Perrie. Professor of Drug Delivery and Head, Institute for Pharmacy and Biomedical Sciences. For services to Pharmaceutical Innovation and Regulation. Timothy Foster Pick.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.